Alcoholic Hepatitis

Differentiating alcoholic hepatitis from NAFLD in patients with significant alcohol consumption can be challenging due to overlapping clinical and histological features. While both conditions can present with elevated liver enzymes, jaundice, and hepatomegaly, certain clues point towards alcoholic hepatitis. A history of heavy alcohol use (typically >80g/day for men and >40g/day for women for several years) is paramount, though not always readily disclosed. Features suggestive of alcoholic hepatitis include a rapid onset of jaundice, ascites, hepatic encephalopathy, and a disproportionately elevated AST to ALT ratio (often 2:1 or greater). Neutrophilic leukocytosis and systemic inflammatory response syndrome (SIRS) criteria are also more common in alcoholic hepatitis. Liver biopsy, while not always necessary, remains the gold standard for definitive diagnosis, revealing characteristic findings like Mallory-Denk bodies, steatosis, and neutrophilic infiltration. However, non-invasive tools such as transient elastography and serum biomarkers are increasingly used to assess liver fibrosis and inflammation, aiding in risk stratification. Consider implementing a thorough patient history, including detailed alcohol consumption patterns, alongside laboratory and imaging findings for accurate differentiation. Explore how incorporating validated questionnaires like the AUDIT-C can improve alcohol use assessment in your practice.

Managing severe alcoholic hepatitis complicated by hepatic encephalopathy and coagulopathy requires a multi-faceted approach. Initial stabilization focuses on airway, breathing, and circulation. Correcting electrolyte imbalances, particularly hypokalemia and hyponatremia, is crucial. Hepatic encephalopathy management includes lactulose administration to reduce ammonia absorption and rifaximin to modulate gut flora. Coagulopathy, often manifested by prolonged INR, requires careful monitoring and fresh frozen plasma (FFP) transfusion if clinically indicated, particularly if invasive procedures are anticipated. Nutritional support is essential, ideally via the enteral route, as malnutrition exacerbates liver injury. Corticosteroids, such as prednisolone or methylprednisolone, are considered in patients with severe alcoholic hepatitis (Maddrey Discriminant Function >=32 or Lille score >=0.45) who do not have active infection or gastrointestinal bleeding. Close monitoring for infection, including spontaneous bacterial peritonitis, is vital, with prompt antibiotic initiation if suspected. In cases refractory to medical management, liver transplantation may be a life-saving option. Learn more about the latest guidelines for managing alcoholic hepatitis complications and explore resources for referral to specialized liver transplant centers.

Several prognostic indicators help predict outcomes in alcoholic hepatitis, guiding treatment strategies and informing patient/family discussions. The Maddrey Discriminant Function (DF) and the Lille score are widely used. The Maddrey DF, calculated using prothrombin time and bilirubin, stratifies patients into low-risk (MDF <32) and high-risk (MDF >=32) groups. The Lille score, assessed after 7 days of corticosteroid therapy, further refines prognosis by evaluating bilirubin, creatinine, INR, albumin, and PT. A Lille score <0.45 suggests a favorable response to corticosteroids, while >=0.45 indicates a poor prognosis and potential need for alternative therapies, including liver transplantation. Other prognostic factors include the Model for End-Stage Liver Disease (MELD) score, which incorporates creatinine, bilirubin, and INR, and the Glasgow alcoholic hepatitis score (GAHS). These tools, combined with clinical judgment, facilitate individualized treatment plans. For patients with a poor prognosis, early discussion about palliative care and potential liver transplant evaluation is crucial. Explore how incorporating these prognostic models into your practice can improve patient outcomes and facilitate informed decision-making.